Safety and efficacy of topical formulations containing 0.5, 1 and 2% glycopyrronium bromide in patients with primary axillary hyperhidrosis: a randomized, double-blind, placebo-controlled study

被引：19
|
作者：
Masur, C. [1 ]
Soeberdt, M. [1 ]
Kilic, A. [1 ]
Knie, U. [1 ]
Abels, C. [1 ]
机构：
[1] Dr August Wolff GmbH & Co KG Arzneimittel, Bielefeld, Germany
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2020年 / 182卷 / 01期
关键词：
D O I：
10.1111/bjd.18234
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：229 / 231
页数：4
相关论文
共 50 条
  • [1] Safety, tolerability, pharmacokinetics and efficacy of Glycopyrronium bromide-containing topical formulations in patients with primary axillary hyperhidrosis
    Abels, C.
    Kilic, A.
    Soeberdt, M.
    Reich, H.
    Knie, U.
    Masur, C.
    EXPERIMENTAL DERMATOLOGY, 2018, 27 (03) : E21 - E22
  • [2] Topical glycopyrronium tosylate in Japanese patients with primary axillary hyperhidrosis: A randomized, double-blind, vehicle-controlled study
    Yokozeki, Hiroo
    Fujimoto, Tomoko
    Wanatabe, Shunsuke
    Ogawa, Shuhei
    Fujii, Chie
    JOURNAL OF DERMATOLOGY, 2022, 49 (01): : 86 - 94
  • [3] Efficacy and Safety of Novel Aspirin Formulations: A Randomized, Double-Blind, Placebo-Controlled Study
    Mollace, Rocco
    Gliozzi, Micaela
    Macri, Roberta
    Tavernese, Annamaria
    Musolino, Vincenzo
    Carresi, Cristina
    Maiuolo, Jessica
    Muscoli, Carolina
    Tomino, Carlo
    Rosano, Giuseppe Maria
    Fini, Massimo
    Volterrani, Maurizio
    Silvestrini, Bruno
    Mollace, Vincenzo
    PHARMACEUTICS, 2022, 14 (01)
  • [4] Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: A 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety
    Lowe, Nicholas J.
    Glaser, Dee Anna
    Eadie, Nina
    Daggett, Simon
    Kowalski, Jonathan W.
    Lai, Pan-Yu
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 56 (04) : 604 - 611
  • [5] A glycopyrronium bromide 1% cream for topical treatment of primary axillary hyperhidrosis: efficacy and safety results from a phase IIIa randomized controlled trial
    Abels, C.
    Soeberdt, M.
    Kilic, A.
    Reich, H.
    Knie, U.
    Jourdan, C.
    Schramm, K.
    Heimstaedt-Muskett, S.
    Masur, C.
    Szeimies, R. -M.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (02) : 315 - 322
  • [6] A randomized, double-blind, placebo-controlled trial of botulinum A toxin for severe axillary hyperhidrosis
    Schnider, P
    Binder, M
    Kittler, H
    Birner, P
    Starkel, D
    Wolff, K
    Auff, E
    BRITISH JOURNAL OF DERMATOLOGY, 1999, 140 (04) : 677 - 680
  • [7] Efficacy and safety of botulinum toxin type A in the treatment of palmar hyperhidrosis: A double-blind, randomized, placebo-controlled study
    Lowe, NJ
    Yamauchi, PS
    Lask, GP
    Patnaik, R
    Iyer, S
    DERMATOLOGIC SURGERY, 2002, 28 (09) : 822 - 827
  • [8] Randomized, double-blind, controlled pilot study of the efficacy and safety of microfocused ultrasound for the treatment of axillary hyperhidrosis
    Nestor, Mark
    Park, Hyunhee
    Nestor, Mark Steven
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 68 (04) : AB59 - AB59
  • [9] EFFICACY AND SAFETY OF QUETIAPINE FOR DELIRIUM IN ICU PATIENTS:A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    Devlin, John W.
    Roberts, Russel
    Fong, Jeffrey J.
    Skrobik, Yoanna
    Harvey, Johanne
    Riker, Richard
    Robbins, Tracey
    Hill, Nicholas
    Garpestad, Erik
    CRITICAL CARE MEDICINE, 2008, 36 (12) : A17 - A17
  • [10] EFFICACY AND SAFETY RESULTS FROM A RANDOMIZED CONTROLLED PHASE 3A STUDY OF 1% GLYCOPYRRONIUM BROMIDE CREAM FOR THE TREATMENT OF PRIMARY AXILLARY HYPERHIDROSIS
    Abels, Christoph
    Soeberdt, Michael
    Kilic, Ana
    Reich, Hubert
    Knie, Ulrich
    Masur, Clarissa
    Szeimies, Rolf-Markus
    ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 54 - 54
12345